产品
编 号：F618863
分子式：C29H29N7O3S
分子量：555.65
分子式：C29H29N7O3S
分子量：555.65
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2254693-15-5
产品详情
生物活性：
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
体内研究：
SRX3207 (10 mg/kg, orally) increases antitumor immune response.Animal Model:LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.
Dosage:10 mg/kg.
Administration:Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result:Blocked phosphorylation of Syk at 348 site and Y525/526 site.Blocked immunosuppressive MΦ polarization.Blocked tumor growth and increased survival effectively.
体外研究：
SRX3207 (10 μmol/L) is able to block p-AKT at concentration.SRX3207 has sufficient solubility in water (43 μmol/L).
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
体内研究：
SRX3207 (10 mg/kg, orally) increases antitumor immune response.Animal Model:LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice.
Dosage:10 mg/kg.
Administration:Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result:Blocked phosphorylation of Syk at 348 site and Y525/526 site.Blocked immunosuppressive MΦ polarization.Blocked tumor growth and increased survival effectively.
体外研究：
SRX3207 (10 μmol/L) is able to block p-AKT at concentration.SRX3207 has sufficient solubility in water (43 μmol/L).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备